Proactive - Interviews for investors

Trident Royalties PLC (AIM:TRR, OTCQX:TDTRF) CEO Adam Davidson joined Proactive's Stephen Gunnion with details of the company's performance for the quarter ended 31 March 2024.

Royalty income approached amounted to US$2.98 million, with a notable performance from its gold offtake portfolio, especially during March which continued into the second quarter due to favourable gold prices. Davidson highlighted seasonal production variations, with reduced outputs in the first quarter generally compensated by higher gold prices.

Significant developments include the full acquisition of Greenstone mine by Equinox Gold, anticipated to produce up to 400,000oz annually for the first five years, and Trident's gold offtake from this mine is expected to contribute substantially to revenue. Davidson also touched on a production expansion at the Blyvoor Gold mine, which could significantly boost Trident's royalties from increased production targets.

Additionally, the US Department of Energy's conditional commitment to loan $2.26 billion for the Thacker Pass lithium development was a crucial milestone, supporting the construction of one of the world's largest lithium deposits, and promising long-term revenue contributions to Trident.

Davidson also discussed the sale of Trident's Australian gold royalty portfolio, which was a strategic move to optimize the asset mix and reinvest capital into new acquisitions, enhancing the company's growth trajectory.

#TridentRoyalties, #GoldRoyalty, #MiningIndustry, #EquinoxGold, #GreenstoneMine, #GoldMarkets, #AdamDavidson, #MiningCEO, #LithiumMining, #ThackerPass, #EnergyDepartmentLoan, #ResourceManagement, #QuarterlyReport, #GoldProduction, #MiningExpansion, #StrategicInvestments, #CorporateStrategy, #ResourceSector, #AustralianGold, #MineralRoyalties

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hostelworld Group PLC (LSE:HSW, OTC:HSWLF) CEO Gary Morrison highlights significant advancements in the company's strategy and operational results in an interview with Proactive's Stephen Gunnion.

The company, a key player in online hostel bookings, introduced social features in its app about two and a half years ago, aiming to enhance user interaction by connecting travellers based on their destination and stay dates. These features have been pivotal in increasing app downloads and subsequently, app-based bookings, which have grown 49% year-over-year, compared to a 27% increase in web bookings.

Hostelworld's innovative social strategy, designed to cater primarily to solo travellers aged 18 to 35, has significantly boosted its market share. This strategy, coupled with an effective marketing approach, has led to a 34% increase in revenue and a 37% increase in net bookings year-over-year.

Morrison also noted a geographical shift in the company's market, with substantial growth in Asia and continued strong performance expected in various global markets.

Furthermore, he discussed the company's financial health, mentioning efficient cash conversion from EBITDA and strategic financial decisions, including a share repurchase program to offset dilution from previous share issuances.

Looking forward, Hostelworld anticipates continued revenue and bookings growth, aligning with its strategic projections established in November 2021.

#HostelworldGroup, #GaryMorrison, #TravelIndustry, #OnlineBooking, #HostelMarket, #AppDevelopment, #SocialFeatures, #SoloTravel, #TravelTrends, #MarketingStrategy, #RevenueGrowth, #BookingApp, #TravelTech, #HostelTravel, #YoungTravelers, #DigitalStrategy, #MarketShare, #FinancialHealth, #ShareRepurchase, #BusinessStrategy #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Mosman Oil and Gas Ltd CEO Andy Carroll discusses the company's recent production increase at the Stanley project in the US, attributing the success primarily to improvements at Stanley-3 well.

Carroll highlighted that optimising production not only boosts revenue but also prepares the project for a potential sale. He revealed the company's strategy to refocus investment towards helium and hydrocarbon sectors, explaining that selling the well-positioned Stanley assets would generate substantial cash, particularly benefiting Australian operations.

Carroll also mentioned the completion of EP 145 Farm-in in Australia following final government approvals, with Greenvale set to fund upcoming seismic and drilling activities. He concluded by noting the strengthened company balance sheet and growing investor interest in helium, indicating a strategic pivot towards this sector for future developments.

#MosmanOilandGas, #AndyCarroll, #OilandGas, #EnergySector, #StanleyProject, #ProductionIncrease, #HeliumInvestment, #Hydrocarbon, #NorthernTerritory, #AustraliaOilGas, #SeismicDrilling, #GreenvalePartnership, #EnergyMarket, #NaturalResources, #CorporateStrategy, #AssetSale, #InvestorInterest, #FinancialHealth, #OperationalSuccess, #IndustryUpdates #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Creo Medical Group PLC (AIM: CREO) CEO Craig Gulliford joins Proactive's Stephen Gunnion with the news that the company has been recognised with the King's Award for Enterprise in Innovation, an accolade honouring innovative UK companies for their impact in their respective sectors.

The award highlights Creo's influence on patient outcomes through their advanced medical technologies. Gulliford emphasised the rare honour, noting that among over five million companies in the UK, only 59 received this award this year.

The company leverages a unique combination of bipolar radiofrequency energy with microwave energy, focusing on miniaturising surgical procedures. This innovation has led to significant advancements in treatment effectiveness and cost-efficiency, particularly noted in a recent NHS case study that showcased substantial economic benefits, including a reduction in theatre costs and patient hospital stays.

This recognition allows Creo Medical Group to join a select group of internationally recognised brands, enhancing their credibility and market presence. Gulliford expressed pride in the team's achievement and optimism about future innovations, particularly in addressing complex medical conditions like lung cancer. The award not only validates past efforts but also sets a high standard for the company's ongoing commitment to healthcare innovation.

#CreoMedicalGroup, #KingsAward, #Innovation, #Healthcare, #MedicalTechnology, #PatientCare, #UKBusiness, #EnterpriseAward, #SurgicalInnovation, #HealthEconomics, #NHS, #HealthcareSavings, #MedicalResearch, #CraigGulliford, #ProXofLondon, #UKCompanies #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

SosTravel.com (OTCQB:SOSAF, EURONEXT:SOS) investor relations head Edoardo Zarghetta outlines the company's operations and strategic directions in an interview with Proactive's Stephen Gunnion.

Sostravel.com operates primarily as a digital travel technology company with two business units. One focuses on packaging holidays, primarily in destinations such as Sardinia, southern Italy, Kenya, Turkey, Egypt, and Cuba, managing hotels and resorts to create custom holiday packages. The second unit provides technology services, including a Lost Luggage Concierge and Dr Travel for telehealth needs, enhancing travellers' experiences by addressing common issues like lost luggage and health care in foreign locales.

The company benefits from a commercial relationship with shareholder TraWell Co SpA (OTCQX:TRWAF), which markets Sostravel.com's services at airports, enhancing visibility and customer acquisition. This relationship allows the implementation of unique marketing strategies focused on leveraging travel needs to introduce value-added services, distinguishing Sostravel.com from competitors by creating a symbiotic ecosystem between holiday offers and service provision.

The company reported a 29.6% increase in gross booking value as of March and projects significant growth in revenues and EBITDA for 2024, with updates expected in August to confirm these forecasts.

#SoSTravel, #TravelTechnology, #HolidayPackages, #DigitalTravel, #InvestorRelations, #TravelServices, #LostLuggage, #Telehealth, #DoctorTravel, #TravelDestinations, #TravelMarketing, #BusinessUnits, #GrossBookingValue, #EBITDA, #TravelInterview, #TravelIndustry, #CommercialRelationship, #TravelCoach, #AirportServices, #B2BTravel #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

URA Holdings PLC (LSE:URAH) CEO Bernard Olivier discusses the company's progress in an interview with Proactive's Stephen Gunnion.

The LSE-listed company has been revitalising its Gravelotte Emerald Mine in South Africa's Limpopo province, achieving operational status in April. The mine, previously the world's largest emerald source, has adopted new technologies such as optical sorters to enhance stone recovery and reduce theft, a significant improvement over past manual processes.

Olivier highlighted his and the management team's extensive experience in the coloured gemstone industry, noting their previous success with TanzaniteOne, which was once the world's largest tanzanite producer. He said many of TanzaniteOne's key management have joined URA Holdings, bringing valuable expertise to the Emerald Mine project.

Currently, the mine has a JORC-compliant resource estimate of 29 million carats, indicating a potential mine life of 10-12 years, with exploration targets suggesting up to 300 million carats available. This substantial resource base has facilitated the upgrade and refurbishment of mining infrastructure and processes.

The first auction of emeralds is planned for the latter half of the year, and URA Holdings aims to keep stakeholders updated via regular communications, including social media updates on platforms like X (Twitter).

#URAHoldings, #BernardOlivier, #EmeraldMining, #GemstoneIndustry, #LondonStockExchange, #MiningTechnology, #OpticalSorters, #EmeraldAuction, #GemstoneMarket, #ResourceEstimation, #MiningInfrastructure, #InvestorUpdates, #ProductionRampUp, #TanzaniteOne, #MineralExploration, #ColouredGemstones, #GemstoneProduction, #EmeraldValue, #SustainableMining, #MiningDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Fusion Antibodies PLC CEO Adrian Kinkaid joined Proactive's Stephen Gunnion with more on the company that specialises in various stages of antibody development, excluding GMP production for clinical trials.

He described Fusion Antibodies as a collaborative research organisation that engages deeply with clients to develop therapeutic antibodies, one of the most complex scientific endeavours. Its client base includes small VC-funded biotechs and has expanded to include large organisations like the National Cancer Institute. Fusion Antibodies also explores adjacent markets such as diagnostics, family medicine, and veterinary medicine.

Recently, the company faced economic challenges, particularly a decrease in venture capital for biotechs, impacting its core business. However, it responded with strategic diversifications and cost management, leading to a 47% increase in fourth-quarter 2024 sales compared to the first quarter. The order pipeline at the year's end was significantly stronger at £750,000, promising a solid foundation for future growth.

Kinkaid noted that Fusion Antibodies has secured various agreements, including a notable collaboration with the National Cancer Institute to employ their OptiMAL technology platform for discovering human antibodies. This platform could potentially lead to multiple licensing opportunities due to its vast diversity.

Additionally, the company raised about £1.37 million, which will fund growth initiatives, including expanding its commercial team to better reach its primary market in the USA.

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #FusionAntibodies #AntibodyDevelopment #Biotech #TherapeuticAntibodies #NationalCancerInstitute #OptiMALTechnology #HealthcareInnovation #Biopharma #VentureCapital #MedicalResearch #Diagnostics #FamilyMedicine #VeterinaryMedicine #BiotechFunding #ClinicalTrials #ResearchCollaboration #ScientificInnovation #Pharmaceuticals #Biotechnology #HealthcareTechnology

Faron Pharmaceuticals Limited (AIM:FARN) new CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with his vision for the company.

The founding member and former chief operating officer of Faron said one of his priorities is to meet with the US Food & Drug Administration earlier than planned in the hope of fast-tracking its lead drug, bexmarilimab, which has shown huge promise in treating a type of rare blood cancer.

The move follows promising data from the phase I trials involving patients with myelodysplastic syndrome (MDS) who were unresponsive to a class of drugs called hypomethylating agents (HMAs).

Jalkanen highlighted the company's ongoing phase 2 trial targeting relapsed refractory MDS, emphasising the strategic goal of securing non-dilutive funding and considering future mergers and acquisitions as the drug shows promise.

Jalkanen also discussed the potential of the lead drug candidate in treating specific macrophage-driven cancers, indicating an optimistic outlook for the near term, including significant milestones expected in 2024. These milestones include more phase 2 data, expected by late May, and subsequent FDA feedback, pivotal for future planning.

The CEO expressed confidence in the company's position and its appeal to investors, especially given the biotech sector's recovery from a period he referred to as a "nuclear winter."

#FaronPharmaceuticals #JuhoJalkanen #Phase2Trials #MDS #FDA #DrugDevelopment #Biotech #Healthcare #Pharmaceuticals #Investment #CancerResearch #Macrophage #ClinicalTrials #MergersAndAcquisitions #Pharma #MedicalInnovation #CEO #Biotechnology #InvestorRelations #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

RC365 Holding PLC (LSE:RCGH) has made significant progress in 2024, according to CEO Michael Law, in an interview with Proactive's Stephen Gunnion.

The company has transitioned 100% of its office operations, including finance, IT, and customer service, to Malaysia and Indonesia, hiring over ten new staff members in the region. RC365 has also won substantial contracts in Japan and secured a £100,000 grant from the Hong Kong Trade and Industry Department to further expand operations in Malaysia.

Furthermore, RC365 agreed to £4 million in loan notes to fund upgrades and enhance its platform, focusing on services like virtual banking. The company's presence in Japan has particularly grown with a contract worth £600,000 aimed at integrating their services into local societal structures.

Law highlighted the company’s strong financial position and pipeline, which includes government grants and significant contracts, enabling sustained development and low-cost operations.

As 2024 progresses, RC365's focus will be on upgrading its platform to support new functionalities such as virtual banking and enhanced payment options. The company also plans to leverage AI for marketing strategies, specifically for online shopping promotions.

#RC365Holding, #Fintech, #VirtualBanking, #Malaysia, #Indonesia, #Japan, #HongKong, #GovernmentGrants, #BusinessDevelopment, #LoanNotes, #C3310, #ITOperations, #FinancialServices, #CustomerService, #AI, #Marketing, #OnlineShopping, #DigitalPayments, #TechIndustry, #BusinessExpansion #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 looked to break new highs yet again as the market opened, this time topping the 8,300 mark.

BP shares failed to contribute to the gains though, as the oil major fell after reporting a significant fall in first-quarter profit and revealing plans to save US$2 billion by late 2026.

Retail sales and house price data unveiled on Tuesday were also skewed, with the former showing a 4.4% fall in April against a year earlier, according to the British Retail Consortium.

House prices increased by 1.1% over the month against a year earlier, but climbed just 0.1% from March, Halifax said, with analysts warning high mortgage rates were still hitting.

Finally, elsewhere, UBS outdid expectations with a first quarterly profit of US$1.8 billion since overtaking Swiss rival Credit Suisse.

#ProactiveInvestors #marketreport #ftse #footsie #ftse100 #bp #ubs #creditsuisse #halifax #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews